Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460551 · ClinicalTrials.gov registry record · Phase 2
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
A Phase 2 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00460551 is a Phase 2 study that was terminated before completion, run by Genmab. The registered enrollment target is 13 participants.
The verdict
NCT00460551, a Phase 2 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.
Interventions
- RADIATION Radiotherapy
- BIOLOGICAL Zalutumumab
- DRUG Induction chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460551
The ClinicalTrials.gov registry entry for NCT00460551 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiotherapy is the first listed.
NCT00460551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460551 about?
NCT00460551 is a clinical study titled "Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer". The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.
What is the current status of trial NCT00460551?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2007-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00460551?
The interventions under investigation include: Radiotherapy (RADIATION), Zalutumumab (BIOLOGICAL), Induction chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00460551?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.